The company continues to report zero revenue while sustaining quarterly operating losses that peaked at $6.5 million in 2024Q2, reflecting a lack of operational leverage.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 6.69K | 15K | 25.57K | 22.53K | 22.78K | 13.07K | 5.88K | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | -6.69K | -15K | -25.57K | -22.53K | -22.78K | -13.07K | -5.88K | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | 100% | 55.39% | 41.33% | -13.5% | 1.07% | -74.27% | -122.09% | - | - | - | - |
| Operating Expenses | 16.04M | 15.52M | 21.17M | 31.06M | 23.81M | 20.65M | 17.94M | 10.67M | 12.36M | 3.31M | 4.13M | 1.07M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 6.41M | 6.09M | 10.63M | 13.44M | 12.3M | 11.68M | 10.64M | 8.7M | 11.39M | 3.02M | 3.78M | 865.7K |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 9.63M | 9.43M | 10.54M | 17.62M | 11.51M | 8.97M | 7.3M | 1.97M | 971.43K | 289.93K | 354.88K | 201.96K |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.88K | 3.24K | 0 | 0 |
| Operating Income | -16.04M | -15.52M | -21.17M | -31.08M | -23.83M | -20.67M | -17.96M | -10.68M | -12.36M | -3.31M | -4.13M | -1.07M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | 26.72% | 31.86% | -30.4% | -15.29% | -15.08% | -68.14% | 13.6% | -273.26% | 19.84% | -286.28% | - |
| EBITDA | -16.02M | -15.49M | -21.17M | -31.06M | -23.81M | -20.65M | -17.94M | -10.67M | -12.36M | -3.31M | -4.13M | -1.07M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 16.29% | 26.83% | 31.85% | -30.48% | -15.29% | -15.1% | -68.13% | 13.66% | -273.44% | 19.9% | -286.95% | - |
| D&A (Non-Cash Add-back) | 1.67K | 0 | 6.69K | 15K | 25.57K | 22.53K | 22.78K | 13.07K | 5.88K | 3.24K | 862 | 2.06K |
| EBIT | -16.03M | -15.49M | -21.11M | -31.08M | -23.74M | -20.66M | -17.94M | -10.65M | -12.33M | -3.31M | -4.13M | -1.07M |
| Net Interest Income | -430.98K | -739.93K | 63.57K | 215.11K | 90.1K | 5.13K | 18.81K | 27.91K | -8.8K | -1.81K | 0 | 0 |
| Interest Income | 24.57K | 0 | 63.57K | 215.11K | 90.1K | 5.13K | 18.81K | 27.91K | 29.18K | 80 | 0 | 0 |
| Interest Expense | 455.55K | 739.93K | 0 | 0 | 0 | 0 | 0 | 0 | 37.98K | 1.89K | 0 | 0 |
| Other Income/Expense | -685.74K | -713.33K | 63K | 215.11K | 90.1K | 5.13K | 18.81K | 27.91K | -8.8K | -1.81K | 0 | 0 |
| Pretax Income | -16.73M | -16.23M | -21.11M | -30.86M | -23.74M | -20.66M | -17.94M | -10.65M | -12.37M | -3.31M | -4.13M | -1.07M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 29.18K | 80 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -0.24% | -0% | 0% | 0% |
| Net Income | -16.73M | -16.23M | -21.11M | -30.86M | -23.74M | -20.66M | -17.94M | -10.65M | -12.37M | -3.31M | -4.13M | -1.07M |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 12.46% | 23.13% | 31.59% | -29.99% | -14.88% | -15.17% | -68.4% | 13.88% | -273.32% | 19.8% | -286.28% | - |
| Net Income (Continuing) | -16.73M | -16.23M | -21.11M | -30.86M | -23.74M | -20.66M | -17.94M | -10.65M | -12.37M | -3.31M | -4.13M | -1.07M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.41 | -17.40 | -266.95 | -1128.00 | -990.00 | -877.50 | -1009.00 | -1329.50 | -1797.00 | -576.50 | -763.00 | -1146.50 |
| EPS Growth % | 93.77% | 93.48% | 76.33% | -13.94% | -12.82% | 13.03% | 24.11% | 26.02% | -211.71% | 24.44% | 33.45% | - |
| EPS (Basic) | - | -17.40 | -266.95 | -1129.00 | -990.00 | -877.50 | -1009.00 | -1332.00 | -1798.50 | -577.50 | -765.00 | -1162.50 |
| Diluted Shares Outstanding | 6.95M | 932.73K | 80.12K | 27.36K | 23.98K | 23.55K | 17.76K | 8.01K | 6.89K | 5.75K | 5.42K | 933 |
| Basic Shares Outstanding | 6.95M | 932.73K | 80.12K | 27.34K | 23.96K | 23.54K | 17.76K | 8K | 6.88K | 5.74K | 5.4K | 920 |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |
Liquidity and dilution risk
As reported in recent financial filings, Genprex maintains a consistent R&D-heavy cost structure, with quarterly research expenditures averaging approximately $2.5 million over the last ten quarters, reflecting the ongoing capital intensity required to advance the REQORSA pipeline through critical clinical trial milestones and manufacturing development.
The company's cost structure is almost entirely comprised of R&D and SG&A, which is typical for a pre-revenue biotechnology firm. Investors should monitor the stability of these costs, as any significant deviation may indicate either unexpected clinical trial delays or a strategic pivot in the development timeline.
Based on the company's historical income statements, Genprex continues to report significant operating losses, with quarterly deficits ranging between $3.3 million and $6.5 million, underscoring the lack of operational leverage inherent in a business model that has yet to achieve commercialization or recurring revenue streams.
The absence of gross profit means that all operating expenses flow directly to the bottom line, resulting in a persistent negative operating margin. This structure necessitates constant external financing, as there is no internal cash generation to offset the high fixed costs of clinical development.
According to the provided financial data, the company's net loss figures are heavily influenced by non-cash items and periodic stock-based compensation, which reached as high as $2.1 million in 2024Q2, complicating the assessment of true operational cash burn for potential equity investors.
The volatility in EPS figures appears to be driven more by capital structure adjustments and equity-based incentives than by changes in core operational efficiency. Analysts should focus on the underlying cash burn rate rather than headline net income to better understand the company's actual runway.
With reported cash reserves of approximately $7.8 million, the company faces a precarious financial position, as historical quarterly burn rates suggest that current liquidity may be insufficient to support long-term clinical trial objectives without further dilutive equity offerings or strategic capital injections.
The reliance on equity markets to fund operations creates a structural risk where shareholder value may be eroded by frequent capital raises. If the company fails to reach a significant clinical inflection point soon, the cost of capital may increase, further pressuring the firm's ability to execute its pipeline strategy.
Quick answers to the most common questions about buying GNPX stock.
For fiscal year 2025, Genprex, Inc. (GNPX) reported total revenue of $0.0M.
Genprex, Inc. (GNPX) reported a net loss of $16.2M for the fiscal year ending 2025.